Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsResearch reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.
The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.
Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.
Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.
IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis
1.
One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types
4.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
5.
According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.
1.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
2.
The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium
3.
Breast Cancer Secrets: AI-Powered Precision Medicine
4.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
5.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Thromboprophylaxis In Medical Settings- An Update
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge